156 related articles for article (PubMed ID: 9048284)
21. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450.
Chen Y; Liu L; Nguyen K; Fretland AJ
Drug Metab Dispos; 2011 Mar; 39(3):373-82. PubMed ID: 21148079
[TBL] [Abstract][Full Text] [Related]
22. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
23. The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo.
Sychev DA; Ashraf GM; Svistunov AA; Maksimov ML; Tarasov VV; Chubarev VN; Otdelenov VA; Denisenko NP; Barreto GE; Aliev G
Drug Des Devel Ther; 2018; 12():1147-1156. PubMed ID: 29780235
[TBL] [Abstract][Full Text] [Related]
24. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
25. Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli.
McGinnity DF; Griffin SJ; Moody GC; Voice M; Hanlon S; Friedberg T; Riley RJ
Drug Metab Dispos; 1999 Sep; 27(9):1017-23. PubMed ID: 10460801
[TBL] [Abstract][Full Text] [Related]
26. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism.
Lewis DF
Biochem Pharmacol; 2000 Aug; 60(3):293-306. PubMed ID: 10856424
[TBL] [Abstract][Full Text] [Related]
27. Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.
Coller JK; Somogyi AA; Bochner F
Br J Clin Pharmacol; 1999 Aug; 48(2):158-67. PubMed ID: 10417492
[TBL] [Abstract][Full Text] [Related]
28. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.
Prakash C; Kamel A; Cui D; Whalen RD; Miceli JJ; Tweedie D
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):35S-42S. PubMed ID: 10771452
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome P450 3A: ontogeny and drug disposition.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
[TBL] [Abstract][Full Text] [Related]
30. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression.
Temesvári M; Kóbori L; Paulik J; Sárváry E; Belic A; Monostory K
J Pharmacol Exp Ther; 2012 Apr; 341(1):294-305. PubMed ID: 22262920
[TBL] [Abstract][Full Text] [Related]
31. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
[TBL] [Abstract][Full Text] [Related]
32. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.
Olesen OV; Linnet K
Br J Clin Pharmacol; 2000 Dec; 50(6):563-71. PubMed ID: 11136295
[TBL] [Abstract][Full Text] [Related]
33. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
Brosen K
Clin Pharmacokinet; 1990 Mar; 18(3):220-39. PubMed ID: 2182263
[TBL] [Abstract][Full Text] [Related]
34. Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.
Wu Y; Chitranshi P; Loukotková L; Gamboa da Costa G; Beland FA; Zhang J; Fang JL
Arch Toxicol; 2017 Jun; 91(6):2405-2423. PubMed ID: 27896399
[TBL] [Abstract][Full Text] [Related]
35. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology.
van der Weide J; Steijns LS
Ann Clin Biochem; 1999 Nov; 36 ( Pt 6)():722-9. PubMed ID: 10586308
[TBL] [Abstract][Full Text] [Related]
36. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants.
Puozzo C; Lens S; Reh C; Michaelis K; Rosillon D; Deroubaix X; Deprez D
Clin Pharmacokinet; 2005; 44(9):977-88. PubMed ID: 16122284
[TBL] [Abstract][Full Text] [Related]
37. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Utkarsh D; Loretz C; Li AP
Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
[TBL] [Abstract][Full Text] [Related]
38. Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.
Derungs A; Donzelli M; Berger B; Noppen C; Krähenbühl S; Haschke M
Clin Pharmacokinet; 2016 Jan; 55(1):79-91. PubMed ID: 26123704
[TBL] [Abstract][Full Text] [Related]
39. Sodium tanshinone IIA sulfonate and its interactions with human CYP450s.
Chen D; Lin XX; Huang WH; Zhang W; Tan ZR; Peng JB; Wang YC; Guo Y; Hu DL; Chen Y
Xenobiotica; 2016 Dec; 46(12):1085-1092. PubMed ID: 26932161
[TBL] [Abstract][Full Text] [Related]
40. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.
Jiang R; Yamaori S; Takeda S; Yamamoto I; Watanabe K
Life Sci; 2011 Aug; 89(5-6):165-70. PubMed ID: 21704641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]